英文药名：UNIPHYL LA tablets（Theophylline）

中文药名：茶碱LA片

生产厂家：大冢制药

ユニフィルLA錠100mg／ユニフィルLA錠200mg／ユニフィルLA錠400mg

治疗类别名称
支气管扩张
商標名
UNIPHYL LA tablets
一般名
テオフィリン（Theophylline）
化学名
1,3-Dimethyl-1H-purine-2,6(3H,7H)-dione
構造式

分子式
C7H8N4O2
分子量
180.16
性状
它是一种白色晶体或结晶粉末。 N，N-二甲基甲酰胺，以容易难溶，在水或乙醇（99.5）微溶。易溶于0.1mol / L的盐酸测试解决方案。
熔点
271〜275℃
适应病症
支气管哮喘，慢性支气管炎，肺气肿
用法用量
成人每天一次，每次400毫克（晚餐口服）。该剂量可以根据年龄和症状进行调整。
药效药理
c-AMP的增加由磷酸二酯酶抑制剂如茶碱，腺苷受体拮抗剂的作用机制，分配调节胞内Ca 2+，从肥大细胞，如隔膜收缩的增加的气管收缩因子游离抑制上升。在支气管哮喘患者中，在ECP（嗜酸性粒细胞阳离子蛋白）值，减少它是嗜酸性粒细胞的总数的细胞毒性蛋白质以及在数量活化嗜酸性粒细胞减少，以及在痰外周血除了呼吸功能的改善消炎作用被认为英寸茶碱，显示出优良的平喘作用这些操作。
另外，在慢性阻塞性肺疾病的患者用此药，痰嗜中性粒细胞，减少了IL-8值和TNF-α的值已报道治疗。
包装规格
LA片剂：
100毫克

[PTP]100片（10片×10），500片（10片×50），700片（14片×50）
200毫克：

[PTP]100片（10片×10），500片（10片×50），700片（14片×50）
[塑料瓶]500粒
400毫克：

[PTP]100片（10片×10），500片（10片×50），700片（14片×50）
[塑料瓶]500粒
制造厂商
大冢制药有限公司
UNIPHYL LA tablets 100mg（ユニフィルLA錠100mg）
Brand name : UNIPHYL LA tablets 100mg
　Active ingredient: Theophylline
　Dosage form: White sustained-release preparation, diameter: 6.4 mm, thickness: 2.9 mm
　Print on wrapping: ユニフィルLA錠100mg, PF U100 Otsuka 100mg
UNIPHYL LA tablets 200mg（ユニフィルLA錠200mg）
Brand name : UNIPHYL LA tablets 200mg
　Active ingredient: Theophylline
　Dosage form: White sustained-release preparation, diameter: 9.5 mm, thickness: 2.8 mm
　Print on wrapping: ユニフィルLA錠200mg, PF U200 Otsuka 200mg
UNIPHYL LA tablets 400mg（ユニフィルLA錠400mg）
Brand name : UNIPHYL LA tablets 400mg
　Active ingredient: Theophylline
　Dosage form: White sustained-release preparation, diameter: 11.0 mm, thickness: 4.1 mm
　Print on wrapping: ユニフィルLA錠400mg, PF U400 Otsuka 400mg
Effects of this medicine
This medicine inhibits the release of bronchoconstriction factors and enhances the contractile function of the diaphragm, thus providing antiasthmatic effects (dilating bronchi to relieve coughing, breathing difficulty, etc.).
It is usually used in the treatment of bronchial asthma, chronic bronchitis and pulmonary emphysema.
Before using this medicine, be sure to tell your doctor and pharmacist
•If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
If you have epilepsy, hyperthyroidism, acute nephritis, congestive heart failure or hepatic disorder.
•If you are pregnant or breastfeeding.
•If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)
Dosing schedule (How to take this medicine)
•Your dosing schedule prescribed by your doctor is <<to be written by a healthcare professional>>
•In general, for adults, take 4 tablets (400 mg of active ingredient) at a time once daily after the evening meal. The dosage may be adjusted according to your disease, age or symptoms. Strictly follow the instructions of your doctor and pharmacist.
•Take this medicine with water and swallow it without chewing because it is a sustained-release preparation.
•If the patient is a child, caregivers should observe conditions of the child. If you notice that the patient develops fever or any abnormalities, consult with your doctor or pharmacist immediately.
•If you miss a dose and remember it before going to bed, take the dose as soon as possible. However, if you take this medicine on an empty stomach, it may cause stomach irritation. If you do not remember that you missed a dose until later (such as after getting up the following morning), skip the missed dose and follow your regular dosing schedule. You should never take two doses at one time.
•If you accidentally take more than your prescribed dose, consult with your doctor or pharmacist.
•Do not stop taking this medicine unless your doctor instructs you to do so.
Precautions while taking this medicine
•This medicine may cause adverse effects if you drink large amounts of beverages containing high levels of caffeine (coffee, black tea, etc.).
•Foods that contain hypericum perforatum (Saint John's wort) may affect the therapeutic effect of this medicine.
•Smoking and quitting smoking may affect the therapeutic effect of this medicine.
•You may see a white substance derived from this medicine in your stool. However, this will not affect the therapeutic effect of the medicine because it is a residue of non-active ingredients of the medicine.
Possible adverse reactions to this medicine
The most commonly reported adverse reactions include rash, headache, dizziness, tremor, insomnia, palpitation, tachycardia, nausea/vomiting, loss of appetite, diarrhea, abdominal pain, dyspepsia (heartburn, etc.), enlarged feeling of abdomen, frequent urination and numbness (around the mouth and tongue). If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
•Sudden muscle contraction, decreased consciousness, language disorder  [convulsion, consciousness disorder, acute encephalopathy]
•Muscle pain in limbs, weakness, reddish brown urine  [rhabdomyolysis]
•Abdominal pain, hematemesis, black stool  [gastrointestinal hemorrhage]
•Breathing difficulty, hives, cold sweat  [anaphylactoid shock]
•General malaise, loss of appetite, yellowing in skin and mucosa  [hepatic dysfunction, jaundice]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.
Storage conditions and other information
•Keep out of the reach of children. Store away from direct sunlight, heat and moisture.
•Discard the remainder. Do not store them. Ask the pharmacist how to discard them.
Otsuka Pharmaceutical Co., Ltd.Internal
Revised: 4/2007
The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.
http://www.info.pmda.go.jp/go/pack/2251001G1076_1_07/